Interventional Pharmacoeconomics

Cancer J. 2020 Jul-Aug;26(4):330-334. doi: 10.1097/PPO.0000000000000461.


The increasing cost of health care is a major challenge around the world, but particularly in the United States. One reason for increased costs is the rapidly rising cost of oncology drugs. Potential solutions to this problem involve broad changes to health policy. However, an alternative solution is the development of lower-cost off-label treatment regimens, based on pharmacologic rationale, with significant potential economic impact. The pharmacologic and clinical properties of many drugs allow for a variety of different strategies. We describe this approach of interventional pharmacoeconomics and provide multiple individual examples.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Economics, Pharmaceutical / standards*
  • Humans